INS and type 1 diabetes mellitus: A clinical trial in 87 recent-onset T1D adult and pediatric patients (treatment: 57 patients, placebo: 30 patients) showed that 4 rituximab infusions significantly preserved 2- and 4-hour AUC C-peptide and lowered insulin requirements (P < .001) and HbA1c levels (P < .001) at 1-year posttreatment (Pescovitz et al, 2009).